Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Will The COVID-19 Pandemic Shake Up Access To Medicines?

Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.

International Europe

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Europe Drug Review

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

South America Chile

Intercept Eyes EU NASH Market

Analysts believe that pan-EU authorization for Intercept Pharmaceuticals’ obeticholic acid for advanced fibrosis due to nonalcoholic steatohepatitis may come in the first quarter of 2021.

Drug Review Europe

Novel Combined Contraceptive Estelle Among Nine New Filings At EMA

Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."

Drug Review Europe

Pricing Reforms Prompt Canadian Business Rethink

The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.

Canada Market Access
See All
UsernamePublicRestriction

Register